(SGHT) Sight Sciences - Overview
Stock: Glaucoma Surgery System, Trabecular Meshwork Device, Dry Eye Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 95.1% |
| Relative Tail Risk | -20.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.29 |
| Alpha | 84.31 |
| Character TTM | |
|---|---|
| Beta | 1.396 |
| Beta Downside | 0.418 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.01% |
| CAGR/Max DD | -0.25 |
Description: SGHT Sight Sciences January 17, 2026
Sight Sciences Inc. (NASDAQ: SGHT) is a U.S.-based ophthalmic medical-device firm that develops and commercializes both surgical and non-surgical treatments for common eye conditions. It operates two business lines: Surgical Glaucoma, anchored by the OMNI® surgical system (an implant-free, single-use platform for combined viscodilation and trabecular meshwork removal) and the SION® bladeless excision instrument; and Dry Eye, centered on the TearCare® system, which uses controlled heat to melt meibomian gland obstructions. The company sells directly to hospitals, eye-care centers, and independent practitioners across the United States and has been publicly traded since its incorporation in 2010.
Key industry metrics that shape SGHT’s outlook include: (1) the U.S. glaucoma market, projected to exceed $4 billion by 2028, driven by an aging population and rising intra-ocular pressure screening rates; (2) dry-eye disease prevalence, estimated at 16 million U.S. adults, supporting a compound annual growth rate (CAGR) of ~6 % for therapeutic devices; and (3) reimbursement trends, where Medicare’s coverage for minimally invasive glaucoma surgery (MIGS) has been expanding, potentially improving SGHT’s price-realization and adoption velocity. As of the latest quarterly filing, SGHT reported $12.3 million in total revenue, with the Surgical Glaucoma segment contributing roughly 68 % and a gross margin of 62 %-both higher than the average for comparable MIGS firms (≈55 %).
For a deeper, data-driven assessment of SGHT’s valuation and risk profile, you may find ValueRay’s analytical report useful.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -46.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -9.36 > 1.0 |
| NWC/Revenue: 133.8% < 20% (prev 159.2%; Δ -25.44% < -1%) |
| CFO/TA -0.27 > 3% & CFO -31.3m > Net Income -46.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.4m) vs 12m ago 4.05% < -2% |
| Gross Margin: 86.05% > 18% (prev 0.85%; Δ 8519 % > 0.5%) |
| Asset Turnover: 58.53% > 50% (prev 55.39%; Δ 3.14% > 0%) |
| Interest Coverage Ratio: -8.19 > 6 (EBITDA TTM -40.5m / Interest Expense TTM 5.01m) |
Altman Z'' -14.74
| A: 0.88 (Total Current Assets 113.6m - Total Current Liabilities 11.8m) / Total Assets 116.3m |
| B: -3.27 (Retained Earnings -380.6m / Total Assets 116.3m) |
| C: -0.32 (EBIT TTM -41.1m / Avg Total Assets 129.9m) |
| D: -7.32 (Book Value of Equity -380.5m / Total Liabilities 52.0m) |
| Altman-Z'' Score: -14.74 = D |
Beneish M -3.27
| DSRI: 0.79 (Receivables 9.74m/12.9m, Revenue 76.1m/79.5m) |
| GMI: 0.99 (GM 86.05% / 85.11%) |
| AQI: 1.17 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 0.96 (Revenue 76.1m / 79.5m) |
| TATA: -0.13 (NI -46.1m - CFO -31.3m) / TA 116.3m) |
| Beneish M-Score: -3.27 (Cap -4..+1) = AA |
What is the price of SGHT shares?
Over the past week, the price has changed by -6.53%, over one month by -21.42%, over three months by +17.40% and over the past year by +116.61%.
Is SGHT a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SGHT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.4 | 59.3% |
| Analysts Target Price | 9.4 | 59.3% |
| ValueRay Target Price | 5.6 | -4.1% |
SGHT Fundamental Data Overview February 03, 2026
P/B = 5.0577
Revenue TTM = 76.1m USD
EBIT TTM = -41.1m USD
EBITDA TTM = -40.5m USD
Long Term Debt = 40.1m USD (from longTermDebt, last quarter)
Short Term Debt = 569.0k USD (from shortTermDebt, last quarter)
Debt = 40.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -51.7m USD (from netDebt column, last quarter)
Enterprise Value = 280.3m USD (332.0m + Debt 40.7m - CCE 92.4m)
Interest Coverage Ratio = -8.19 (Ebit TTM -41.1m / Interest Expense TTM 5.01m)
EV/FCF = -8.80x (Enterprise Value 280.3m / FCF TTM -31.8m)
FCF Yield = -11.36% (FCF TTM -31.8m / Enterprise Value 280.3m)
FCF Margin = -41.87% (FCF TTM -31.8m / Revenue TTM 76.1m)
Net Margin = -60.63% (Net Income TTM -46.1m / Revenue TTM 76.1m)
Gross Margin = 86.05% ((Revenue TTM 76.1m - Cost of Revenue TTM 10.6m) / Revenue TTM)
Gross Margin QoQ = 86.39% (prev 84.78%)
Tobins Q-Ratio = 2.41 (Enterprise Value 280.3m / Total Assets 116.3m)
Interest Expense / Debt = 3.21% (Interest Expense 1.31m / Debt 40.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -32.4m (EBIT -41.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.60 (Total Current Assets 113.6m / Total Current Liabilities 11.8m)
Debt / Equity = 0.63 (Debt 40.7m / totalStockholderEquity, last quarter 64.3m)
Debt / EBITDA = 1.28 (negative EBITDA) (Net Debt -51.7m / EBITDA -40.5m)
Debt / FCF = 1.62 (negative FCF - burning cash) (Net Debt -51.7m / FCF TTM -31.8m)
Total Stockholder Equity = 74.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.49% (Net Income -46.1m / Total Assets 116.3m)
RoE = -61.59% (Net Income TTM -46.1m / Total Stockholder Equity 74.9m)
RoCE = -35.72% (EBIT -41.1m / Capital Employed (Equity 74.9m + L.T.Debt 40.1m))
RoIC = -28.31% (negative operating profit) (NOPAT -32.4m / Invested Capital 114.6m)
WACC = 10.13% (E(332.0m)/V(372.7m) * Re(11.06%) + D(40.7m)/V(372.7m) * Rd(3.21%) * (1-Tc(0.21)))
Discount Rate = 11.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.50%
Fair Price DCF = unknown (Cash Flow -31.8m)
EPS Correlation: 88.67 | EPS CAGR: 102.4% | SUE: 3.63 | # QB: 2
Revenue Correlation: 49.64 | Revenue CAGR: 8.45% | SUE: 2.45 | # QB: 3
EPS next Quarter (2026-03-31): EPS=-0.17 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=-0.64 | Chg30d=-0.042 | Revisions Net=+1 | Growth EPS=+17.5% | Growth Revenue=+11.3%